Reducing Postoperative Needling in XEN63<sup>®</sup> Surgery with Adjunctive Cross-Linked Hyaluronic Acid Implant (Healaflow<sup>®</sup>): Early Evidence from Real-World Practice.

J Clin Med · 2025 · PMC12387734 · PMID 40869674

Europe PMC DOI

hedged sentence

0.2430

closest p · 4.9× alpha

0.2430

boldest claim

The sentences

did not reach statistical significancep = 0.243not close (p > 0.1)

The Mann–Whitney U test comparing the number of procedures between the two groups did not reach statistical significance ( p = 0.243) while a two-proportions z-test revealed a significant difference in total procedure frequency ( p = 0.004), indicating a substantially higher postoperative intervention burden in the XENa group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Reducing Postoperative Needling in XEN63&lt;sup&gt;®&lt;/sup&gt; Surgery with Adjunctive Cross-Linked Hyaluronic Acid Implant (Healaflow&lt;sup&gt;®&lt;/sup&gt;): Early Evidence from Real-World Practice.

The sentences

Reducing Postoperative Needling in XEN63<sup>®</sup> Surgery with Adjunctive Cross-Linked Hyaluronic Acid Implant (Healaflow<sup>®</sup>): Early Evidence from Real-World Practice.